Physician profile
Michael Warren Pelster
NPI 1699017145
$9,663.27
in general payments reported to CMS, 2019-2025
37 companies · $2,490 in 2025
The $2,490 reported for 2025 was more than what 91% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $207 · 2021: $492 · 2022: $1,695 · 2023: $2,011 · 2024: $1,640 · 2025: $2,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,747 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,747.37 |
| Education | $394.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,645.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,379.85 | 2019-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $1,005.70 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $669.15 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $505.19 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $435.54 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $429.51 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $400.08 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $380.01 | 2019-2025 | Oracea, Aklief, Epsolay |
| Novartis Pharmaceuticals Corporation | $378.41 | 2019-2025 | |
| Ucb, INC. | $373.69 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $262.77 | 2021-2025 | |
| Almirall LLC | $233.69 | 2019-2025 | Seysara |
| Genzyme Corporation | $222.98 | 2019-2025 | |
| Organogenesis INC. | $135.43 | 2023-2025 | Puraply, Puraply Wound Matrix |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $126.08 | 2022 | |
| Merz North America, INC. | $121.07 | 2019-2020 | |
| Leo Pharma INC. | $108.16 | 2020-2025 | Adbry, Anzupgo |
| Janssen Scientific Affairs, LLC | $102.70 | 2019 | |
| Mayne Pharma Commercial LLC | $89.86 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.70 | 2019-2025 | Cabtreo, Jublia |
| Progenacare Global, LLC | $70.35 | 2023 | |
| Arcutis Biotherapeutics, INC. | $65.07 | 2024-2025 | Zoryve |
| Organon LLC | $62.46 | 2025 | Vtama |
| Epi Health, LLC | $61.00 | 2021-2022 | |
| Genentech USA, INC. | $52.06 | 2021-2022 | |
| Botanix Sb INC | $51.22 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $38.85 | 2025 | Acthar |
| Convatec INC. | $35.15 | 2025 | |
| Dermavant Sciences, INC. | $30.48 | 2022-2023 | Vtama |
| Vyne Pharmaceuticals INC. | $26.58 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.75 | 2024 | Spevigo |
| Journey Medical Corporation | $17.40 | 2022 | |
| Mindera Corp | $14.43 | 2025 | |
| Mimedx Group, INC. | $14.19 | 2024 | |
| Bioventus LLC | $12.78 | 2022 | |
| Biofrontera INC. | $7.59 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pelster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.